Revance Therapeutics Inc (RVNC)

[DewDiligence]

3Q23 worldwide Botox sales=$1.368B, -5% QoQ*, flat YoY:

https://news.abbvie.com/news/press-releases/abbvie-reports-second-quarter-2023-financial-results.htm

• US therapeutic: $626M (+2% QoQ, +7% YoY)
• US cosmetic: $388M (-8% QoQ*, +5% YoY)
--
US total: $1.014B (62% therapeutic; 39% cosmetic) was 74% of worldwide total


• Ex-US therapeutic: $122M (-9% QoQ, +9% YoY†)
• Ex-US cosmetic: $235M (-12% QoQ, -11% YoY†)
--
Ex-US total: $337M (34% therapeutic; 66% cosmetic) was 26% of worldwide total.


†Ex-US YoY growth measured in local currency, which eliminates the effect of fluctuating exchange rates.

*In the US market, botulinum-toxin sales for cosmetic indications are seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.